Home NEWS AND MEDIA

NEWS AND MEDIA

Dec 2023

NeuExcell's AAV Gene Therapy for Malignant Glioma Granted Orphan Drug Designation by FDA

Learn more
May 2023

NeuExcell Therapeutics Raises $15+ Million Pre-A+ Round

Philadelphia, PA., May 4, 2023– NeuExcell Therapeutics (www.neuexcell.com), a gene therapy company focusing on neurodegenerative diseases, has announced a $15+ million Series Pre-A+ financing round.

Learn more
Oct 2022

Five Startups Enliven the Gene Therapy Scene in Asia

Learn more
Aug 2021

NeuExcell Therapeutics raises $10+ million series Pre-A round to continue Its company growth

STATE COLLEGE, Pa., Aug. 30, 2021 /PRNewswire/ -- NeuExcell Therapeutics (www.neuexcell.com), a gene therapy company

Learn more
Mar 2020

Novel gene therapy generated new functional neurons in mouse models of Huntington's Disease (HD)

Nature Communications Publication Demonstrates Proof of Principle for Neuroregenerative Approach Pioneered by Founder and Chief Scientific Officer of NeuExcell Therapeutics

Learn more